date:Oct 04, 2012
f the day, Young said, there is no imminent public health risk in the reports findings.
Whether FDA should expend substantial resources doing the kinds of things that were suggested is a decision that FDA would have to make with regard to all of the other public health priorities, he said.
The report might go overboard in its enforcement recommendations, Ullman said, but that doesnt obviate legitimate questions about how some companies market their products.
As an industry we need to recogniz